<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="44423">Hydroxyurea</z:chebi> is an established drug that has been used for the treatment of <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> and some <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> for some time </plain></SENT>
<SENT sid="1" pm="."><plain>In recent years it has also been found to be effective in the treatment of <z:e sem="disease" ids="C0002895" disease_type="Disease or Syndrome" abbrv="">sickle cell disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Short term side effects are not serious, and are manageable </plain></SENT>
<SENT sid="3" pm="."><plain>The major concern is the potential <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> with long term use </plain></SENT>
<SENT sid="4" pm="."><plain>The risk of <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> is not defined with its use in benign hematological conditions </plain></SENT>
<SENT sid="5" pm="."><plain>We report a case of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with no preceding <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, occurring after 2 years of <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> therapy in a patient with <z:e sem="disease" ids="C0002895" disease_type="Disease or Syndrome" abbrv="">sickle cell disease</z:e> </plain></SENT>
</text></document>